16:04 , Jul 11, 2018 |  BC Innovations  |  Translation in Brief

Poisoning the stromal chalice

A study published in the Journal of Clinical Investigation suggests antibody-drug conjugates targeting the tumor stroma could treat cancers by co-opting a stromal mechanism to feed cytotoxic drugs to the surrounding tumor cells. Tumor-associated stroma, which...
21:13 , Apr 17, 2018 |  BC Innovations  |  Distillery Techniques

Disease models; drug properties

TECHNOLOGY: 3-D models; pharmacokinetics/pharmacodynamics 3-D human intestinal organoids could be used to test the PK properties of drug compounds. The organoids are generated by culturing human induced pluripotent stem (iPS) cells in a medium containing fibroblast...
23:03 , Jan 25, 2018 |  BC Extra  |  Financial News

Follow-on roundup: Audentes, Iovance

At least six companies have priced follow-ons since Wednesday’s market close, raising more than $600 million. Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) raised $201.3 million after hours on Wednesday through the sale of 5.8...
00:30 , Oct 20, 2017 |  BC Week In Review  |  Clinical News

DSMB backs Athenex's Phase III breast cancer trial of Oraxol

Athenex Inc. (NASDAQ:ATNX) said an independent DSMB recommended continuation of the Phase III Oraxol 001 trial of Oraxol to treat metastatic breast cancer based on interim safety and overall response rate (ORR) data. The open-label, international...
18:00 , Aug 16, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Self-assembling multicellular BBB spheroids could help screen compounds for BBB permeability. The spheroids self-assembled from co-cultures of primary human astrocytes, brain vascular pericytes and either brain microvascular endothelial cells or a human cerebral...
23:29 , Jun 14, 2017 |  BC Extra  |  Financial News

Athenex ticks up after $66M IPO

Cancer company Athenex Inc. (NASDAQ:ATNX) gained $1.56 (14%) to $12.56 in its first day of trading Thursday after it raised $66 million through the sale of 6 million shares at $11 in an IPO underwritten...
16:10 , Jun 7, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Cell models iPS cell-derived brain microvascular endothelial cells could serve as BBB models for HD or Allan-Herndon-Dudley syndrome. The cells were generated by co-culturing iPS cells derived from patients in endothelial cell-conditioned media with fibroblast...
14:06 , May 16, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture studies suggest that artificial vesicles loaded with Zybrestat fosbretabulin and doxorubicin could help treat doxorubicin-resistant breast cancer. The artificial vesicles consisted of amphiphilic block co-polymers loaded with Zybrestat fosbretabulin and doxorubicin....
07:00 , Sep 15, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: ATP-binding cassette sub-family B member 1 (ABCB1; MDR1; PGP; CD243)

Cancer INDICATION: Leukemia Cell culture studies suggest inhibiting ABCB1 could help treat chemotherapy-resistant leukemia. In a human leukemia cell line resistant to the generic chemotherapy doxorubicin, an ABCB1 inhibitor tool compound increased sensitivity to doxorubicin compared with...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Clinical News

Savaysa: Phase IIIb data

Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan   Product: Savaysa ( Lixiana - EU) edoxaban (DU-176b)   Business: Cardiovascular   Molecular target: Factor Xa   Description: Oral Factor Xa inhibitor   Indication: Prevent stroke and systemic embolism in patients with...